Credit put spread analysis · · Moderate setup
Earlier analyses
-
The IV picture matters here: 20% IV is cheap, but realized vol is 67% — that's a screaming mismatch. The stock is up 33% in two months, so this 9% drop is just a pullback in a strong uptrend. Key support is around $10.50…
-
[dedup-flagged] The IV picture matters here: at 25%, it's cheap relative to the 68% realized vol, but that's a red flag. The stock is up 33% in two months and just got hammered 9% with no reversal signal. That's a moment…
-
The selloff looks dramatic until you realize the stock is still up 33% in two months — this is a pullback in a strong uptrend, not a breakdown. IV at 100% is rich, but it's justified by 70% realized vol; the premium actu…
-
The IV picture matters here: at 100% it's rich, but that's the only thing paying you for this biotech's inherent volatility. The chart shows a 43% rocket over two months, so this -8% drop is just a cooldown, not a breakd…
-
[dedup-flagged] The IV picture matters here: at 69% it's rich, but the 98% realized vol says you're still not getting paid enough for the daily fireworks. The chart shows a rocket that's up 43% in two months hitting a wa…
AI analysis
Options Trader · Jul 20, 2026
The AI's notes below mention opening a position, but the rating (3.2/5) sits below our public-display threshold of 3.5/5, so this setup is marked Hold rather than as a tradable idea.
Before you touch this spread, reconcile the 70% realized volatility with a 23% IV. The math says IV is rich, but the chart shows a rocket that just blew a gasket — up 33% in two months before a 9% flush. That's a volatile floor.
Key support around $10. 50 needs to hold; a break there and the 200-day SMA is miles below. For a defined-risk play, sell the $10.
50 put and buy the $9. 50 put for a $0. 30 credit.
It's a 1:4 risk/reward, which just clears our floor, but you're getting paid for the risk of catching a falling biotech knife. Verdict: A speculative nibble, not a meal.